AZD8965 low dose

Phase 2

AZD8965 low dose is one of 2 therapeutic programs targeting Idiopathic Pulmonary Fibrosis (IPF). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Idiopathic Pulmonary Fibrosis (IPF)Recruiting

Idiopathic Pulmonary Fibrosis (IPF)Phase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Idiopathic Pulmonary Fibrosis (IPF)

#DrugCompanyPhaseTrials

LTI-03

RRein Therapeutics

Phase 2

1 2

AZD8965 low dose

AstraZeneca

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2Recruiting

Idiopathic Pulmonary Fibrosis (IPF)

NCT07652658

Clinical

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants With Idiopathic Pulmonary Fibrosis (IPF) (ARGiNAUT)

Recruiting· AstraZeneca logo

AstraZeneca·Phase 2·NCT07652658·359 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AZD8965 low dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AZD8965 low dose. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AstraZeneca

AZD8965 low dose

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Idiopathic Pulmonary Fibrosis (IPF)1 trial

References

Drug Info

Quick Facts

Related News